1. Key Insights

2. Report Introduction

3. Atopic Dermatitis Market Overview at a Glance

3.1 Market Share (%) Distribution of Atopic Dermatitis by Drug-class in 2024

3.2 Market Share (%) Distribution of Atopic Dermatitis by Drug-class in 2032

4. Epidemiology and Market Methodology

5. Executive Summary

5.1 Key Events

6. Disease Background and Overview

6.1 Signs and Symptoms

6.2 Causes and Triggers

6.3 Clinical Presentation

6.4 Pathophysiology

6.5 Skin Hypersensitivity – Abnormalities of the Horny Cell Layer

6.5.1 Mechanisms involved in inflammation

6.5.2 Pruritus

6.5.2.1 Pathophysiology of pruritus in atopic dermatitis

6.5.2.2 Alarmins and neuropeptides

6.5.2.3 Interkeukins (IL)-4, IL-13, and IL-31

6.5.2.4 Janus kinase/signal transducer and activator of transcription

6.5.2.5 Opioid system

6.6 Biomarkers

6.7 Serum IgE levels

6.7.1 Peripheral eosinophil count

6.7.2 Serum lactate dehydrogenase level

6.7.3 Serum thymus and activation regulated chemokine level

6.8 Characteristics of eruption

6.8.1 Infancy (younger than 2 years)

6.8.2 Childhood/school-age (2–12 years)

6.8.3 Adolescence/adulthood (13 years)

6.9 Differential Diagnosis

6.10 Prevention and Management

6.11 Diagnosis

6.12 Diagnostic Criteria for Eczema

6.13 Treatment

6.13.1 Topical treatment

6.13.1.1 Emollients

6.13.1.2 Topical corticosteroids (TCs)

6.13.1.3 Topical calcineurin inhibitors (TCIs)

6.13.2 Systemic Treatment

6.13.2.1 Immunosuppressants

6.13.2.2 Oral corticosteroids

6.13.2.3 Interleukin inhibitors

6.13.2.4 JAK inhibitors

6.13.2.5 PDE4 inhibitor

6.13.2.6 Phototherapy

6.13.2.7 Antibiotics

6.13.2.8 Antihistamines

6.13.2.9 Capsaicin

6.13.2.10 Systemic agents for treating pruritus in atopic dermatitis

6.13.3 Self-care

6.13.3.1 Bathing practices

6.13.3.2 Wet wrap therapy (WWT)

6.13.3.3 Stress-relieving therapies

6.14 Treatment and Diagnosis Guidelines

6.14.1 Atopic Dermatitis Clinical Guideline: American Academy of Dermatology Association (2014)

6.14.1.1 Guidelines for diagnosis and assessment

6.14.1.1.1 Recommendation for the diagnosis of atopic dermatitis

6.14.1.1.2 Recommendations for the use of biomarkers in the assessment of atopic dermatitis

6.14.1.1.3 Recommendations for disease severity and clinical outcomes assessment

6.14.1.1.4 Recommendations for the assessment of clinical associations of atopic dermatitis

6.14.1.2 Guidelines for management and treatment with topical therapies

6.14.1.2.1 Recommendations for nonpharmacologic interventions for the treatment of atopic dermatitis

6.14.1.2.2 Recommendations for the use of topical corticosteroids for the treatment of atopic dermatitis

6.14.1.2.3 Recommendations for the use of topical calcineurin inhibitors for the treatment of atopic dermatitis

6.14.1.2.4 Recommendations for the use of topical antimicrobials and antiseptics for the treatment of atopic dermatitis

6.14.1.2.5 Recommendations for the use of topical antihistamines for the treatment of atopic dermatitis

6.14.1.3 Guidelines for Management and Treatment with Phototherapy and Systemic Agents

6.14.1.3.1 Recommendations for the use of phototherapy

6.14.1.3.2 Recommendations for the use of systemic immunomodulatory agents

6.14.1.3.3 Dosing and monitoring guidelines for the use of selected systemic agents

6.14.1.3.4 Recommendations for the use of systemic antimicrobials

6.14.1.3.5 Recommendations for the use of systemic antihistamines

6.14.1.4 Prevention of disease flares and use of adjunctive therapies and approaches

6.14.1.4.1 Recommendation for prevention of flares of atopic dermatitis

6.14.1.4.2 Recommendations for educational interventions for atopic dermatitis

6.14.1.4.3 Recommendations for testing for co-existing allergic disease

6.14.1.4.4 Recommendations for other adjunctive and complementary interventions for the treatment of atopic dermatitis

6.14.2 Atopic eczema in under 12s: diagnosis and management by NICE (updated 2020)

6.14.2.1 Assessment of severity, psychological and psychosocial well-being, and quality of life

6.14.2.1.1 Identification and management of trigger factors

6.14.2.2 Treatment

6.14.2.2.1 Recommendations for the use of emollients

6.14.2.2.2 Recommendations for the use of topical corticosteroids

6.14.2.2.3 Recommendations for the use of topical calcineurin inhibitors

6.14.2.2.4 Recommendations for the use of dry bandages and medicated dressings, including wet wrap therapy

6.14.2.2.5 Recommendations for the use of antihistamines

6.14.2.2.6 Recommendations for the treatments for infections

6.14.2.2.7 Recommendations for the use of phototherapy and systemic treatments

6.14.2.2.8 Recommendations for the use of complementary therapies

6.14.2.2.9 Recommendations for education and adherence to therapy

6.14.2.2.10 Recommendations of indications for referral

6.14.3 European guideline (EuroGuiDerm) on atopic eczema: Part I – systemic therapy (2022)

6.14.4 European guideline (EuroGuiDerm) on atopic eczema: Part II – European guideline (EuroGuiDerm) on atopic eczema: Part I – systemic therapy (2022)

6.15 Treatment Algorithm

6.15.1 Japanese Guidelines for atopic dermatitis 2020

6.15.2 Treatment Algorithm of atopic dermatitis in Early Childhood

7. Epidemiology and Patient Population

7.1 Key Findings

7.2 Assumption and Rationale

7.2.1 United States

7.2.2 EU4 and the UK

7.2.3 Japan

7.3 Total Prevalent Cases of atopic dermatitis in the 7MM

7.4 Epidemiology Scenario in the US

7.4.1 Total Prevalent Cases of atopic dermatitis in the US

7.4.2 Total Prevalent Cases of atopic dermatitis by age in the US

7.4.3 Total Diagnosed Cases of atopic dermatitis in the US

7.4.4 Total Diagnosed Cases of atopic dermatitis by Severity in the US

7.4.5 Total Diagnosed Cases of atopic dermatitis by Gender in the US

7.4.6 Total Treated Cases of atopic dermatitis in the US

7.5 Epidemiology Scenario in EU4 and the UK

7.5.1 Total Prevalent Cases of atopic dermatitis in EU4 and the UK

7.5.2 Total Prevalent Cases of atopic dermatitis by age in EU4 and the UK

7.5.3 Total Diagnosed Cases of atopic dermatitis in EU4 and the UK

7.5.4 Total Diagnosed Cases of atopic dermatitis by Severity in EU4 and the UK

7.5.5 Total Diagnosed Cases of atopic dermatitis by Gender in EU4 and the UK

7.5.6 Total Treated Cases of atopic dermatitis in EU4 and the UK

7.6 Epidemiology Scenario in Japan

7.6.1 Total Prevalent Cases of atopic dermatitis in Japan

7.6.2 Total Prevalent Cases of atopic dermatitis by age in Japan

7.6.3 Total Diagnosed Cases of atopic dermatitis in Japan

7.6.4 Total Diagnosed Cases of atopic dermatitis by Severity in Japan

7.6.5 Total Diagnosed Cases of atopic dermatitis by Gender in Japan

7.6.6 Total Treated Cases of atopic dermatitis in Japan

8. Patient Journey

9. Key Endpoints in atopic dermatitis Clinical Trials

10. Marketed Therapies

10.1 Key Competitors

10.2 MITCHGA (nemolizumab): Chugai Pharmaceutical/Galderma/Maruho

10.2.1 Product description

10.2.2 Regulatory milestones

10.2.3 Other developmental activities

10.2.4 Pivotal clinical trial

10.2.4.1 Summary of pivotal clinical trial

10.2.5 Ongoing pipeline activity

10.2.5.1 Clinical trials information

10.3 MOIZERTO (difamilast): Otsuka Pharmaceutical/Medimetriks Pharmaceuticals/Acrotech Biopharma

10.3.1 Product description

10.3.2 Regulatory milestones

10.3.3 Other developmental activities

10.3.4 Pivotal clinical trial

10.3.4.1 Summary of pivotal clinical trial

10.3.5 Ongoing pipeline activity

10.3.5.1 Clinical trials information

10.4 EUCRISA (crisaborole): Pfizer

10.4.1 Product description

10.4.2 Regulatory milestones

10.4.3 Other developmental activities

10.4.4 Pivotal clinical trial

10.4.4.1 Summary of pivotal clinical trial

10.5 RINVOQ (upadacitinib): AbbVie

10.5.1 Product description

10.5.2 Regulatory milestones

10.5.3 Other developmental activities

10.5.4 Pivotal clinical trial

10.5.4.1 Summary of pivotal clinical trial

10.5.5 Ongoing pipeline activity

10.5.5.1 Clinical trials information

10.6 CIBINQO (abrocitinib): Pfizer

10.6.1 Product description

10.6.2 Regulatory milestones

10.6.3 Other developmental activities

10.6.4 Pivotal clinical trial

10.6.4.1 Summary of pivotal clinical trial

10.6.5 Ongoing pipeline activity

10.6.5.1 Clinical trials information

10.7 ADBRY/ADTRALZA (tralokinumab): LEO Pharma

10.7.1 Product description

10.7.2 Regulatory milestones

10.7.3 Pivotal clinical trial

10.7.3.1 Summary of pivotal clinical trial

10.7.4 Ongoing pipeline activity

10.7.4.1 Clinical trials information

10.8 OPZELURA (ruxolitinib): Incyte Corporation

10.8.1 Product description

10.8.2 Regulatory milestones

10.8.3 Other developmental activities

10.8.4 Pivotal clinical trial

10.8.4.1 Summary of pivotal clinical trial

10.8.5 Ongoing pipeline activity

10.8.5.1 Clinical trials information

10.9 DUPIXENT (dupilumab): Sanofi/Regeneron Pharmaceuticals

10.9.1 Product description

10.9.2 Regulatory milestones

10.9.3 Other developmental activities

10.9.4 Pivotal clinical trial

10.9.4.1 Summary of pivotal clinical trial

10.9.5 Ongoing pipeline activity

10.9.5.1 Clinical trials information

10.9.6 Safety and efficacy

10.10 CORECTIM Ointment (delgocitinib): Japan Tobacco/Leo Pharma/Torii Pharmaceutical

10.10.1 Product description

10.10.2 Regulatory milestones

10.10.3 Other developmental activities

10.10.4 Pivotal clinical trial

10.10.4.1 Summary of pivotal clinical trial

10.11 OLUMIANT (baricitinib): Eli Lilly and Company/Incyte Corporation

10.11.1 Product description

10.11.2 Regulatory milestones

10.11.3 Other developmental activities

10.11.4 Pivotal clinical trial

10.11.4.1 Summary of pivotal clinical trial

10.11.5 Ongoing pipeline activity

10.11.5.1 Clinical trials information

11. Emerging Therapies

11.1 Key Cross Competition - Emerging Therapies

11.2 Rocatinlimab (KHK4083/AMG 451): Amgen/Kyowa Kirin

11.2.1 Product description

11.2.2 Other developmental activities

11.2.3 Clinical developmental activities

11.2.3.1 Clinical trial information

11.2.4 Safety and efficacy

11.3 Lebrikizumab: Dermira/Eli Lilly and Company/Almirall

11.3.1 Product description

11.3.2 Other developmental activities

11.3.3 Clinical developmental activities

11.3.3.1 Clinical trial information

11.3.4 Safety and Efficacy

11.4 VTAMA (tapinarof; JTE-061): Dermavant Sciences/Japan Tobacco Pharmaceutical/Torii Pharmaceutical

11.4.1 Product description

11.4.2 Other developmental activities

11.4.3 Clinical developmental activities

11.4.3.1 Clinical trial information

11.4.4 Safety and Efficacy

11.5 KAPRUVIA/KORSUVA (difelikefalin): Cara Therapeutics

11.5.1 Product description

11.5.2 Other developmental activities

11.5.3 Clinical developmental activities

11.5.3.1 Clinical trial information

11.5.4 Safety and efficacy

11.6 Etrasimod: Pfizer/Arena Pharmaceuticals

11.6.1 Product description

11.6.2 Other developmental activities

11.6.3 Clinical developmental activities

11.6.3.1 Clinical trial information

11.6.4 Safety and efficacy

11.7 ZORYVE (roflumilast): Arcutis Biotherapeutics

11.7.1 Product description

11.7.2 Other developmental activities

11.7.3 Clinical developmental activities

11.7.3.1 Clinical trial information

11.7.4 Safety and efficacy

11.8 Orismilast: UNION Therapeutics

11.8.1 Product Description

11.8.2 Other developmental activities

11.8.3 Clinical developmental activities

11.8.3.1 Clinical trial information

11.9 Amlitelimab: Kymab/Sanofi

11.9.1 Product description

11.9.2 Clinical developmental activities

11.9.2.1 Clinical trial information

11.9.3 Safety and efficacy

12. Atopic Dermatitis: The 7MM Analysis

12.1 Key Findings

12.2 Market Outlook

12.3 Conjoint Analysis

12.4 Key Market Forecast Assumptions

12.5 Total Market Size of AD in the 7MM

12.6 The United States Market Size

12.6.1 Total market size of atopic dermatitis in the US

12.6.2 Market size of atopic dermatitis by therapies in the US

12.7 EU4 and the UK Market Size

12.7.1 Total market size of atopic dermatitis in EU4 and the UK

12.7.2 Market size of atopic dermatitis by therapies in EU4 and the UK

12.8 Japan Market Size

12.8.1 Total market size of atopic dermatitis in Japan

12.8.2 Market size of atopic dermatitis by therapies in Japan

13. Market Access and Reimbursement

13.1 The United States

13.1.1 Centre for Medicare and Medicaid Services (CMS)

13.2 In EU4 and the UK

13.2.1 Germany

13.2.2 France

13.2.3 Italy

13.2.4 Spain

13.2.5 United Kingdom

13.3 Japan

13.3.1 MHLW

13.4 Market Access and Reimbursement of atopic dermatitis

13.4.1 Key HTA decisions

13.4.2 Patient Access Programs

14. KOL Views

15. SWOT Analysis

16. Unmet Needs

17. Appendix

17.1 Acronyms and Abbreviations

17.2 Bibliography

17.3 Report Methodology

18. DRACapabilities

19. Disclaimer